Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: BiondVax Pharmaceuticals Ltd. BVXV

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases – with a primary focus on diseases underserved by current treatments and with … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference

The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunitiesBiondVax’s lead … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured in The Times of Israel Article

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. The company’s CEO Amir Reichman, as an international subject matter expert on pharmaceutical manufacturing … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is ‘One to Watch’

BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023BiondVax has exclusive options for worldwide licenses for NanoAbs to … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment